Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

New Study Shows Potential for Experimental Asthma Pill

By Ryan Bushey | August 8, 2016

Researchers at the University of Leicester announced promising results for what could be the first new asthma pill in nearly 20 years.

The primary goal of this study was to see how the drug, Feviviprant, affected airway inflammation by measuring the patient’s sputum eosinophil count, according to the university’s announcement. It’s essentially a biological marker that analyzes how severe the condition is based on an increase in certain types of white blood cells.

A total of 61 patients with moderate-to-severe asthma participated in this study where one group was assigned placebo and the other group was given 225 milligrams of the drug that needed to be taken twice a day over the course of 12 weeks. Both sets of volunteers were required to take the medication in conjunction with their current treatment regimen.

Results showedFeviviprant significantly improved lung function and fixed damaged airways in lungs as well as decreased asthma symptoms and reduced inflammation with no serious adverse events reported.

Novartis is developing the drug, reported Reuters. The company hopes to file for regulatory approval in 2019 after more tests are done verifying that Feviviprant can reduce severe asthma attacks.


Filed Under: Drug Discovery

 

Related Articles Read More >

Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority
Portrait photo of Pfizer EVP and Medtronic board member Lidia Fonseca
Medtronic appoints Pfizer EVP as independent board director

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50